Gleevec (known as imatinib) has a significant therapeutic effect in the early stages of chronic myeloid leukemia (CML), targeting the BCR-Abl tyrosine kinase (TK) (Kantarjian et al., 2012). This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.